A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Andrea Wang‐Gillam, Stacey M. Plambeck-Suess, Peter S. Goedegebuure, Peter O. Simon, Jonathan B. Mitchem, John R. Hornick, Steven Sorscher, Joel Picus, Rama Suresh, A. Craig Lockhart,

Investigational New Drugs · 2012 · 96 citations · 23 references

DOIFull text

Open access

Concepts

References

23